China Shineway Pharmaceutical
China Shineway Pharmaceutical Group Limited, commonly referred to as Shineway Pharmaceutical, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1997, the company has made significant strides in the development and manufacturing of traditional Chinese medicine and modern pharmaceuticals, with a strong operational presence across Asia and beyond. Shineway Pharmaceutical is renowned for its core products, including herbal medicines and innovative therapeutic solutions, which are distinguished by their quality and efficacy. The company has achieved notable milestones, such as receiving various certifications for its manufacturing processes, solidifying its reputation in the market. With a commitment to research and development, Shineway continues to enhance its product offerings, positioning itself as a leader in the pharmaceutical sector and contributing to the global healthcare landscape.
DitchCarbon Score
How does China Shineway Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
China Shineway Pharmaceutical's score of 31 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
China Shineway Pharmaceutical's reported carbon emissions
In 2023, China Shineway Pharmaceutical reported total carbon emissions of approximately 140,340,570 kg CO2e. This figure includes 80,760,440 kg CO2e from Scope 1 emissions, 38,727,160 kg CO2e from Scope 2, and 20,852,970 kg CO2e from Scope 3 emissions. Over the years, the company has shown a trend of decreasing emissions, with a notable reduction from 153,410,000 kg CO2e in 2017 to the latest figure in 2023. The company has not publicly committed to specific reduction targets or initiatives, nor does it appear to have set science-based targets (SBTi) for emissions reduction. However, it continues to disclose its emissions data across all three scopes, indicating a level of transparency in its climate reporting. Overall, while China Shineway Pharmaceutical has made progress in reducing its carbon footprint, further commitments and initiatives would enhance its climate strategy and align it with global sustainability goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 117,620,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 8,186,000 | 00,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 27,604,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
China Shineway Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
